Apr 23, 2021 09:07 JST

Source: Eisai

Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease

TOKYO, Apr 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Biogen (Nasdaq: BIIB) has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab, an investigational treatment for Alzheimer's disease, in countries other than the United States, Japan, and in Europe which have been announced previously.

In the first quarter of 2021 Biogen submitted a MAA to Ag?ncia Nacional de Vigil?ncia Sanit?ria (ANVISA) in Brazil for aducanumab an investigational treatment for Alzheimer's disease. This application is currently in queue for review.

Biogen also submitted MAAs for aducanumab to Health Canada, the Therapeutic Goods Agency in Australia, and Swissmedic in Switzerland, all of which are subject to agency validation of whether the applications are accepted.

Aducanumab is being jointly developed by Biogen and Eisai.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
June 15 2021 08:00 JST
 
Eisai Receives Special Prize at Platinum Career Award 2021
June 09 2021 12:44 JST
 
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)
June 09 2021 10:31 JST
 
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM
June 08 2021 13:09 JST
 
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease
June 08 2021 08:47 JST
 
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib
June 08 2021 07:19 JST
 
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
May 31 2021 17:54 JST
 
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting
May 20 2021 08:36 JST
 
Anticancer Agent "Remitoro Intravenous Drip Infusion 300 microgram" (Denileukin Diftitox (Genetical Recombination)) Launched in Japan
May 19 2021 11:27 JST
 
Eisai and National Cancer Center Commence Joint Research and Development Project
May 14 2021 16:48 JST
 
More Press release >>

Latest Press Release


More Latest Release >>